A Phase 2 interventional study of Cyclophosphamide and Bortezomib in Multiple Myeloma, sponsored by Janssen-Cilag International NV. Completed at 43 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-01-15.
Sponsored by Janssen-Cilag International NV (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 271 studies testing bortezomib in Multiple Myeloma — 12 open to participants now, 40 under way, 14 of them phase 3. Bortezomib · Multiple Myeloma.
Among the 271 studies testing bortezomib in Multiple Myeloma, this one is the 37th largest by enrollment of the 267 interventional ones that give a count, is one of 22 that started in 2008, is one of 137 in phase 2, and was the 116th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →12 of the 271 studies testing bortezomib in Multiple Myeloma are open now, in 10 countries. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 18+
Canadian Myeloma Research Group · Sites in Canada
Ages 65+
Peking University First Hospital · Sites in China
Ages 18–70
Stichting European Myeloma Network · Sites in Austria, Germany, Greece and 2 more countries
Ages 18–70
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
271 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 76 · Phase 2 176 · Phase 3 46 · Phase 4 8
First in 1999; this study’s year is marked. 22 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 163 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 41 across the 267 interventional studies. Of the 194 that completed or were terminated, 94 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 271 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen-Cilag International NV, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen-Cilag International NV is the lead sponsor of 67 studies on the registry; none are open to participants now.
126 studies in Multiple Myeloma by Johnson & Johnson: 13 open now, 33 under way, 12 of them phase 3. Of 82 finished, 33 (40%) have results posted.
Among the 126 studies in Multiple Myeloma by Johnson & Johnson, this one is the 44th largest by enrollment of the 100 interventional ones that give a count, is one of 6 that started in 2008, is one of 32 in phase 2, and was the 28th registered.
Johnson & Johnson’s Multiple Myeloma studies by the year they started, since 1995.
9 of the studies testing bortezomib in Multiple Myeloma that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03729804Phase 3University of ChicagoCarfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) | 2026-12-28 |
| NCT03319667Phase 3SanofiA Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | 2027-04-05 |
| NCT05665140Phase 3University Hopsital Schleswig Holstein Campus LübeckExpression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | 2027-08 |
| NCT00734877Phase 3University of ArkansasUARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma | 2027-09 |
| NCT02718833Massachusetts General HospitalA Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma | 2026-12 |
Add all 9 to your calendar (.ics) → With an account.
Among the 271 studies testing bortezomib in Multiple Myeloma, from their registry updates:
Among Johnson & Johnson’s 126 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to test the effectiveness and safety of adding cyclophosphamide or lenalidomide to the VD combination in the treatment of patients with multiple myeloma that have achieved a stable response after 4 initial cycles of treatment with VD. Multiple myeloma is the second most common cancer of the blood. Bortezomib disrupts the life cycle of the cell, affecting numerous biologic pathways, including those related to growth and survival of cancer cells.
It has been shown that quality of response corresponds with clinical benefit. Stable disease is not regarded as a satisfactory result of therapy for relapsed and refractory multiple myeloma. However, there is no consensus if, when and how treatment should be continued or changed in the case of stable disease.
There are different strategies of achieving an optimal quality of response in relapsed and refractory multiple myeloma. One is to treat for a longer duration with one regimen. The alternative path can be a sequential approach adding another agent to the initial regimen depending on the outcome of therapy after a defined treatment period. These two principles will be evaluated in the present study.
Both Cyclophosphamide and Lenalidomide have proven to be efficacious in multiple myeloma and combinations of both agents with bortezomib and Dexamethasone have been shown to be active and tolerable.
In this study patients with relapsed/progressive or refractory multiple myeloma will start treatment with bortezomiib and Dexamethasone. Response will be evaluated after four cycles. Patients with complete, very good partial response or partial response will continue treatment as initiated. Patients with stable disease will either continue treatment with the bortezomib/Dexamethasone combination for another four cycles or will receive Cyclophosphamide or Lenalidomide as an additional third agent for another four cycles.
Patients with multiple myeloma that are refractory to or have relapsed/progressed after primary treatment for multiple myeloma will be enrolled in the study. All patients will receive a combination of bortezomib plus dexamethasone for a total of four cycles. Based on the response to this treatment, further study treatment is customized. Patients with a complete, a very good partial or a partial response will continue to receive bortezomib and Dexamethasone for a maximum additional four cycles, to an overall maximum of eight cycles. Patients achieving stable disease, as defined by International Myeloma Working Group 2006 (IMWG 2006) response criteria, will undergo a central randomisation to continue treatment with VD or VD plus cyclophosphamide or VD plus lenalidomide. Patients with progressive disease will go off study treatment. After randomisation, patients will receive therapy for up to four additional treatment cycles, to an overall maximum of eight cycles. Each cycle will consist of three weeks treatment. There will be a long-term follow-up period with monthly visits until relapse or progressive disease. Thereafter follow-up for survival will be continued by at least a phone call every other month. This will be performed for all patients until the last patient was treated and followed up for 1 year.
Safety will be assessed by the monitoring of adverse events, physical examination (including neurological/peripheral neurological examinations), pulmonary examinations, vital signs measurements, and clinical laboratory tests.
Patients will be treated in a 3-week cycle, up to a maximum of 8 cycles bortezomib 1.3 mg/m2 will be administered on day 1, 4, 8 and 11 as i.v. bolus infusion.
Dexamethasone 20 mg po will be administered on days 1, 2, 4, 5, 8, 9, 11, 12. Dexamethasone will be administered as 2 tables of 8 mg plus 1 tablet of 4 mg Cyclophosphamide 500 mg po will be administered as 10 tablets of 50 mg on day 1, 8, 15 Lenalidomide will be administered as once daily 10 mg tablet from day 1 to 14
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stable disease after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8
Drug: Bortezomib · Drug: Dexamethasone
Stable disease after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8 and 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8 and cyclophosphamide 500 mg, orally daily, days 1, 8 and 15 for cycle 5 to 8
Drug: Cyclophosphamide · Drug: Bortezomib · Drug: Dexamethasone
Stable disease after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8 and 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8 and lenalidomide 10 mg orally daily from day 1 to day 14 for cycle 5 to 8
Drug: Bortezomib · Drug: Dexamethasone · Drug: Lenalidomide
Complete, very good partial or partial response after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8
Drug: Bortezomib · Drug: Dexamethasone
500 mg, p.o daily, days 1, 8 and 15 for cycles 5 to 8 cycles
1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 for cycles 1 to 8
20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycles 1 to 8
10 mg orally daily, days 1-14 for cycles 5 to 8
Overall Best Confirmed Response
Overall Best Confirmed Response is the best Overall Response Rate with borezomib-dexamathasone (+/-cyclophosphamide or lenalidomide) recorded between baseline and end of treatment. Response was assessed using the International Myeloma working Group (IMWG) Uniform Response Criteria and validated by an Independent Monitoring Committee.
Time frame: Prior to treatment at day 1 of each cycle and at the end of treatment (day 21 of cycle 8), up to 168 days
Median Time to First Confirmed Response
Time from start of treatment to the date of the first documentation of a confirmed response. Estimated using the Kaplan-Meier method. Response was assessed using the International Myeloma Working Group (IMWG) Uniform Response Criteria and validated by an Independent Monitoring Committee.
Time frame: At Day 1 of each treatment cycle, at the End of Treatment visit until there is evidence of Progressive Disease or relapse from Complete Response (CR), up to 168 days
Progression Free Survival
Time from start of treatment to date of disease progression, relapse from CR or death. Estimated using the kaplan-meier method. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions", or similar definition as accurate and appropriate.
Time frame: At Day 1 of each treatment cycle, at the End of Treatment visit until there is evidence of Progressive Disease or relapse from Complete Response (CR). Median Follow-Up of 16.9 months
Time to Progression
Is calculated as the time from start of treatment to the date of the first observation of disease progression or relapse from CR. Deaths owing to causes other than progression not counted, but censored. Subjects who withdraw from the study or die will be censored at the time of last disease assessment. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0).
Time frame: At Day 1 of each treatment cycle, at the End of Treatment visit until there is evidence of Progressive Disease or relapse from Complete Response (CR), Median Follow-up of 16.9 months
One Year Survival
Percent Probability of Survival at 1 year from the start of treatment, estimated using Kaplan-Meier analysis.
Time frame: At each visit from baseline to end of treatment. After treatment, monthly visit until progression or relapse or until the start of alternative MMY therapy, up to 1 year
Overall Survival
Is defined as the time interval from start of treatment to the date of death due to any cause. In the absence of confirmation of death (including subjects lost to follow-up), survival time will be censored at the last date the subject is known to be alive
Time frame: At each visit from baseline to end of treatment. After treatment, monthly visit until progression or relapse or until the start of alternative MMY therapy. Further follow up by monthly phone call until the last patient was treated and followed for 1 year
| Milestone | Cycle 1 to 4: Bortezomib + Dexamethasone (VD) | Stable Disease: Bortezomib + Dexamethasone (VD) | SD: Bortezomib+Dexamethasone+Cyclophosphamide (VDC) | SD: Bortezomib+Dexamethasone+Lenalidomide (VDR) |
|---|---|---|---|---|
| Started | 163 | 0 | 0 | 0 |
| Completed | 135 | 0 | 0 | 0 |
| Not completed | 28 | 0 | 0 | 0 |
| Withdrew: Death | 5 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 6 | 0 | 0 | 0 |
| Withdrew: Adverse event | 12 | 0 | 0 | 0 |
| Withdrew: Other | 1 | 0 | 0 | 0 |
| Milestone | Cycle 1 to 4: Bortezomib + Dexamethasone (VD) | Stable Disease: Bortezomib + Dexamethasone (VD) | SD: Bortezomib+Dexamethasone+Cyclophosphamide (VDC) | SD: Bortezomib+Dexamethasone+Lenalidomide (VDR) |
|---|---|---|---|---|
| Started | 98 | 7 | 8 | 4 |
| Completed | 63 | 4 | 7 | 4 |
| Not completed | 35 | 3 | 1 | 0 |
| Withdrew: Complete response/partial response | 1 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 5 | 0 | 0 | 0 |
| Withdrew: Death | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 0 | 1 | 0 |
| Withdrew: Adverse event | 17 | 2 | 0 | 0 |
| Withdrew: Physician decision | 2 | 0 | 0 | 0 |
| Withdrew: Other | 3 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 |
Overall Best Confirmed Response is the best Overall Response Rate with borezomib-dexamathasone (+/-cyclophosphamide or lenalidomide) recorded between baseline and end of treatment. Response was assessed using the International Myeloma working Group (IMWG) Uniform Response Criteria and validated by an Independent Monitoring Committee.
| number of participants | Complete to Partial Response: Bortezomib + Dexamethasone | Stable Disease After 4 Cycles: VD, VDC, VDL |
|---|---|---|
| Overall Best Confirmed Response | 101 | 6 |
Time from start of treatment to the date of the first documentation of a confirmed response. Estimated using the Kaplan-Meier method. Response was assessed using the International Myeloma Working Group (IMWG) Uniform Response Criteria and validated by an Independent Monitoring Committee.
| days | Complete to Partial Response: Bortezomib + Dexamethasone | Stable Disease After 4 Cycles: VD, VDC, VDL |
|---|---|---|
| Median Time to First Confirmed Response | 43.0 (43.0 to 58.0) | NA (152.0 to NA) |
Time from start of treatment to date of disease progression, relapse from CR or death. Estimated using the kaplan-meier method. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions", or similar definition as accurate and appropriate.
| days | Complete to Partial Response: Bortezomib + Dexamethasone | Stable Disease After 4 Cycles: VD, VDC, VDL |
|---|---|---|
| Progression Free Survival | 311.0 (224.0 to 424.0) | 214.0 (198.0 to 234.0) |
Is calculated as the time from start of treatment to the date of the first observation of disease progression or relapse from CR. Deaths owing to causes other than progression not counted, but censored. Subjects who withdraw from the study or die will be censored at the time of last disease assessment. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0).
| days | Complete to Partial Response: Bortezomib + Dexamethasone | Stable Disease After 4 Cycles: VD, VDC, VDL |
|---|---|---|
| Time to Progression | 366.0 (281.0 to 475.0) | 214.0 (198.0 to 234.0) |
Percent Probability of Survival at 1 year from the start of treatment, estimated using Kaplan-Meier analysis.
| percent probability | Complete to Partial Response: Bortezomib + Dexamethasone | Stable Disease After 4 Cycles: VD, VDC, VDL |
|---|---|---|
| One Year Survival | 80 (73 to 87) | 89 (62 to 97) |
Is defined as the time interval from start of treatment to the date of death due to any cause. In the absence of confirmation of death (including subjects lost to follow-up), survival time will be censored at the last date the subject is known to be alive
| days | Complete to Partial Response: Bortezomib + Dexamethasone | Stable Disease After 4 Cycles: VD, VDC, VDL |
|---|---|---|
| Overall Survival | NA (888.0 to NA) | NA (982.0 to NA) |
Collected over From signing of informed consent until 30 days after the last dose of study medication (approximately 7 months) or longer if considered related to study medication.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Complete to Partial Response: Bortezomib + Dexamethasone | — | 59/144 (41%) | 137/144 (95.1%) |
| Stable Disease After 4 Cycles: VD, VDC, VDL | — | 6/19 (31.6%) | 19/19 (100%) |
| Event | Complete to Partial Response: Bortezomib + Dexamethasone | Stable Disease After 4 Cycles: VD, VDC, VDL |
|---|---|---|
| PneumoniaInfections and infestations | 9/144 | 0/19 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/144 | 1/19 |
| Deep Vein ThrombosisVascular disorders | 0/144 | 1/19 |
| Cardiac FailureCardiac disorders | 3/144 | 1/19 |
| PyrexiaGeneral disorders | 3/144 | 1/19 |
| Oedema PeripheralGeneral disorders | 2/144 | 1/19 |
| Lower Respiratory Tract InfectionInfections and infestations | 3/144 | 1/19 |
| BronchopneumoniaInfections and infestations | 1/144 | 1/19 |
| Hepatitis BInfections and infestations | 0/144 | 1/19 |
| ThrombocytopeniaBlood and lymphatic system disorders | 6/144 | 0/19 |
| Event | Complete to Partial Response: Bortezomib + Dexamethasone | Stable Disease After 4 Cycles: VD, VDC, VDL |
|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 52/144 | 8/19 |
| AnaemiaBlood and lymphatic system disorders | 29/144 | 6/19 |
| ConstipationGastrointestinal disorders | 45/144 | 5/19 |
| DiarrhoeaGastrointestinal disorders | 45/144 | 5/19 |
| Oedema PeripheralGeneral disorders | 38/144 | 5/19 |
| FatigueGeneral disorders | 37/144 | 0/19 |
| AstheniaGeneral disorders | 29/144 | 4/19 |
| PyrexiaGeneral disorders | 15/144 | 4/19 |
| Peripheral Sensory NeuropathyNervous system disorders | 29/144 | 4/19 |
| NeuralgiaNervous system disorders | 22/144 | 4/19 |
modified Intent to Treat Population consisting of all 163 participants with at least 1 dose and 1 post baseline efficacy assessment.: Complete and Partial Responders (non-randomized), n=144. Stable Disease (randomized to VD, VDC, and VDL), n=19.
| Age, Continuous(years) | All Study Participants |
|---|---|
| Mean | 63.7 ± 11.04 |
| Sex: Female, Male(Participants) | All Study Participants |
|---|---|
| Female | 77 |
| Male | 86 |
| Region of Enrollment(participants) | All Study Participants |
|---|---|
| France | 20 |
| Germany | 15 |
| Greece | 23 |
| Hungary | 2 |
| Lithuania | 9 |
| Poland | 19 |
| Serbia | 15 |
| Spain | 20 |
| Turkey | 19 |
| United Kingdom | 21 |
The record gives a start of May 2008, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2012, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bortezomib · Dexamethasone
Janssen-Cilag International NV →